LEO Pharma Gains FDA Priority Review for Dersimelagon
BALLERUP, Denmark — September 18, 2026 LEO Pharma announced that the U.S. Food and Drug Administration (FDA) has accepted...
LEO Pharma
Advertisement
LEO Pharma Gains Positive CHMP Opinion for Anzupgo
BALLERUP, Denmark — September 18, 2026 LEO Pharma announced that the European Medicines Agency’s Committee for Medicinal Products for...
LEO Pharma Expands Dermatology Pipeline After H1 Growth
BALLERUP, Denmark — August 18, 2026 LEO Pharma reported continued momentum in its dermatology business during the first half...
LEO Pharma Wins China Approval for Enstilar Psoriasis Drug
BALLERUP, Denmark, April 17, 2026 LEO Pharma A/S has secured a major regulatory milestone with the approval of Enstilar®...
LEO Pharma Gains FDA sNDA Acceptance for ANZUPGO
Madison, New Jersey, U.S. | April 15, 2026 LEO Pharma has announced that the U.S. Food and Drug Administration...
Advertisement
